Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Actuate Therapeutics (NASDAQ: ACTU) announced that President & CEO Dan Schmitt will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 9:20 a.m. ET.
The presentation will be webcast and posted under Events in the Investors section of the company website, and a replay will be available on the company website for 30 days following the presentation. Management will hold one-on-one investor meetings at the conference.
Positive
- None.
Negative
- None.
Market Reaction – ACTU
Following this news, ACTU has gained 7.71%, reflecting a notable positive market reaction. Our momentum scanner has triggered 2 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $4.05. This price movement has added approximately $7M to the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
ACTU fell 8.96% while momentum-screened peers GLSI and AVTX moved up 3.08% and 9.66%, indicating a stock-specific move rather than a sector-wide trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 21 | Pipeline expansion | Positive | +5.4% | Planned Phase 1/2 elraglusib tablet program in refractory cancers with 2H 2026 start. |
| Jan 12 | Phase 2 data | Positive | -6.3% | Randomized Phase 2 pancreatic cancer trial met primary endpoint with survival benefit. |
| Jan 06 | Phase 1 pediatric data | Positive | +5.0% | Positive outcomes in refractory pediatric cancers and Rare Pediatric Designations. |
| Dec 18 | ASCO GI selection | Positive | +2.3% | Phase 2 pancreatic data selected for oral and poster presentations at ASCO GI 2026. |
| Dec 15 | Phase II publication | Positive | -8.8% | Published positive Phase II salivary gland carcinoma data with extended survival metrics. |
Recent clinical catalysts have produced mixed reactions: three positive-price responses and two notable sell-offs despite positive trial updates.
Over the past few months, Actuate reported multiple positive clinical updates for elraglusib across pancreatic, pediatric, and salivary gland cancers, often tied to major meetings like ASCO GI 2026. Price reactions were inconsistent: gains of 5.4%, 5.05%, and 2.33% followed some data, while other favorable results saw declines of 6.35% and 8.78%. Today’s conference-participation news fits a pattern of active scientific and investor engagement rather than a new efficacy or financing catalyst.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration filed on 2025-09-02, allowing future offerings of common stock, debt, warrants, and units via prospectus supplements such as the 424B5 filings on 2025-09-09 and 2025-09-10.
Market Pulse Summary
The stock is up +7.7% following this news. A strong positive reaction aligns with Actuate’s pattern of sharp moves around visibility events, such as prior clinical data and conference presentations. Historical reactions ranged from gains of 2–5% to declines of 6–9% on news. Investors have also faced past equity offerings under the existing shelf framework. Such financing flexibility and mixed historical responses suggest that enthusiasm after conference exposure can be tempered by funding and execution risks.
Key Terms
glycogen synthase kinase-3 beta (GSK-3β) medical
AI-generated analysis. Not financial advice.
CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026 at 9:20 a.m. ET.
The webcast of Mr. Schmitt’s presentation will be available at:
The Actuate management team is scheduled to host one-on-one meetings with investors and attendees during the conference. Registered attendees can request one-on-one meetings with Actuate management via their Oppenheimer banking representative.
The presentation will also be located under “Events” in the Investors section of the Company’s website at www.actuatetherapeutics.com. A replay of the webcast will be available on Actuate’s website for 30 days following the presentation.
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and DNA Damage Response (DDR). Elraglusib may also mediate anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function.
For additional information, please visit the Company’s website at www.actuatetherapeutics.com or follow us on LinkedIn, X, and Facebook.
Forward Looking Statements
This press release contains forward-looking statements about us, including our and other parties’ clinical trials and development plans, and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements related to present facts or current conditions or of historical facts, contained in this press release are forward-looking statements. Accordingly, these statements involve estimates, assumptions, substantial risks and uncertainties which could cause actual results to differ materially from those expressed in them, including but not limited to that preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or following a more comprehensive review of the data and should not be relied upon as a final analysis; clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes, results of prior preclinical studies, early clinical trials and sub-group studies are not necessarily predictive of future results and may not correlate with improved responses, and elraglusib may not achieve positive clinical results or favorable preclinical results or receive regulatory approval on a timely basis, if at all; that we may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose for such development; that elraglusib could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials or result in other negative consequences; our reliance on third parties to conduct our non-clinical studies and our clinical trials; our reliance on third-party licensors and ability to preserve and protect our intellectual property rights; that we face significant competition from other biotechnology and pharmaceutical companies; our ability to fund development activities, including because our financial condition raises substantial doubt as to our ability to continue as a going concern and we require additional capital to finance our operations beyond the second quarter of fiscal year 2026, and a failure to obtain this necessary capital in the near term on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations. In addition, any forward-looking statements are qualified in their entirety by reference to the factors discussed under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 13, 2025, and our Quarterly Reports on Form 10-Q, and other filings with the SEC. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Investor Contact
Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media Contact
Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310
FAQ
When will Actuate Therapeutics (ACTU) present at the Oppenheimer Healthcare Life Sciences conference?
How can investors watch the Actuate (ACTU) presentation webcast on February 26, 2026?
Will Actuate Therapeutics (ACTU) make a replay of the February 26, 2026 presentation available?
How can registered attendees request one-on-one meetings with Actuate (ACTU) management at the conference?
Where on Actuate Therapeutics' website will the February 26, 2026 presentation be posted?
Who from Actuate Therapeutics (ACTU) will present at the Oppenheimer conference and what is his role?
